CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
to Standard Of Care in adult patients with aggressive B-cell Non-Hodgkin Lymphoma after failure of rituximab and anthracyc...
Phase 3
London, United Kingdom and 66 other locations
The primary objective of this study is to characterize the safety and tolerability of loncastuximab tesirine in combination with polatuzumab vedotin,...
Phase 1
London, United Kingdom and 34 other locations
and young adult participants with recurrent or refractory classical Hodgkin lymphoma and non-Hodgkin lymphoma...
Phase 1, Phase 2
London, United Kingdom and 75 other locations
This is a global Phase 2, open-label, single-arm, multicohort, multicenter study to evaluate efficacy and safety of JCAR017 in adult subjects with r/...
Phase 2
London, United Kingdom and 56 other locations
(CAR) targeting CD19 in pediatric patients with relapsed or refractory (r/r) B cell acute lymphoblastic leukemia (B ALL) and r/r B cell Non- ...
Phase 1
London, United Kingdom and 5 other locations
The goal of this multicenter study is to test JNJ-90009530 in Relapsed or Refractory Non-Hodgkin Lymphoma Patients. The ma...
Phase 1
London, United Kingdom and 14 other locations
additional open-label imaging feasibility sub-study using a tracer in adult participants with relpased/refractory B-cell non-Hodgkin...
Phase 1, Phase 2
London, United Kingdom and 19 other locations
targeting both cluster of differentiation (CD) CD19 and CD20 for the treatment of adult participants with relapsed or refractory B-Cell non- ...
Phase 1
London, United Kingdom and 25 other locations
This study will evaluate the safety, efficacy, and pharmacokinetics of mosunetuzumab or glofitamab in combination with CELMoDs (CC-220 and/or CC-9928...
Phase 1
London, United Kingdom and 26 other locations
with polatuzumab vedotin in participants with diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and mantle cell lymphoma...
Phase 1, Phase 2
Cambridge, United Kingdom and 28 other locations
Clinical trials
Research sites
Resources
Legal